Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25575509,flow rate,"The mobile phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH 3.5) and methanol (25:75, v/v), flowing through XBridge BEH (50 × 2.1 mm ID, 5 µm) C18 column, at a flow rate of 0.6 mL min(-1).","Simultaneous Determination of Aliskiren Hemifumarate, Amlodipine Besylate and Hydrochlorothiazide in Spiked Human Plasma Using UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25575509/),[ml] / [min],0.6,2283,DB00177,Valsartan
,17884739,flow rate,"The mobile phase consisting of a mixture of acetonitrile and 0.05 mM formic acid (50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min.",Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884739/),[ml] / [min],0.25,3007,DB00177,Valsartan
,20329655,Cmax,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[ng] / [ml],3067.7,6856,DB00177,Valsartan
,20329655,Cmax,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[ng] / [ml],"3,304.3",6857,DB00177,Valsartan
,20329655,AUC0-48,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[h·ng] / [ml],"17,834.4",6858,DB00177,Valsartan
,20329655,AUC0-48,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[h·ng] / [ml],"18,319.1",6859,DB00177,Valsartan
,20329655,AUC0-infinity,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[h·ng] / [ml],"18,825.7",6860,DB00177,Valsartan
,20329655,AUC0-infinity,"The obtained values for test and reference products were 3067.7 +/- 1,281.7 and 3,304.3 +/- 1,196.4 ng/ml for Cmax; 17,834.4 +/- 7,083.8 and 18,319.1 +/- 7,800.7 ng x h/ml for AUC0-48; 18,825.7 +/- 7,553.2 and 19,172.2 +/- 8,307.2 ng x h/ml for AUC0-infinity, respectively.",Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20329655/),[h·ng] / [ml],"19,172.2",6861,DB00177,Valsartan
,27230850,half-life,"However, the steady-state Cmax of sacubitrilat was increased by ∼60 % in patients irrespective of degree of renal impairment; half-life increased from 12 h (in healthy subjects) to 21.1, 23.7, and 38.5 h, respectively; and AUC0-24h was increased 2.10-, 2.24-, and 2.70-fold, respectively, in patients with mild, moderate, and severe renal impairment.","Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230850/),h,12,15774,DB00177,Valsartan
,27230850,half-life,"However, the steady-state Cmax of sacubitrilat was increased by ∼60 % in patients irrespective of degree of renal impairment; half-life increased from 12 h (in healthy subjects) to 21.1, 23.7, and 38.5 h, respectively; and AUC0-24h was increased 2.10-, 2.24-, and 2.70-fold, respectively, in patients with mild, moderate, and severe renal impairment.","Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230850/),h,21.1,15775,DB00177,Valsartan
,27230850,half-life,"However, the steady-state Cmax of sacubitrilat was increased by ∼60 % in patients irrespective of degree of renal impairment; half-life increased from 12 h (in healthy subjects) to 21.1, 23.7, and 38.5 h, respectively; and AUC0-24h was increased 2.10-, 2.24-, and 2.70-fold, respectively, in patients with mild, moderate, and severe renal impairment.","Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230850/),h,23.7,15776,DB00177,Valsartan
,27230850,half-life,"However, the steady-state Cmax of sacubitrilat was increased by ∼60 % in patients irrespective of degree of renal impairment; half-life increased from 12 h (in healthy subjects) to 21.1, 23.7, and 38.5 h, respectively; and AUC0-24h was increased 2.10-, 2.24-, and 2.70-fold, respectively, in patients with mild, moderate, and severe renal impairment.","Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230850/),h,38.5,15777,DB00177,Valsartan
,12491811,elimination half-life,"The elimination half-life was about 4-6 h, valsartan was poorly metabolized, and most of the drug was excreted via feces.","[Preclinical and clinical profile of Valsartan, a selective angiotensin II type-1 receptor blocker]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12491811/),h,4-6,21570,DB00177,Valsartan
,24529292,AUC0-∞,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),[h·ng] / [ml],"31,784",22436,DB00177,Valsartan
,24529292,AUC0-∞,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),[h·ng] / [ml],"32,714",22437,DB00177,Valsartan
,24529292,Cmax,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),[ng] / [ml],5094,22438,DB00177,Valsartan
,24529292,Cmax,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),[ng] / [ml],5064,22439,DB00177,Valsartan
,24529292,Tmax,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),h,2.92,22440,DB00177,Valsartan
,24529292,Tmax,"The mean AUC0-∞ values with the test and reference tablets were 31,784 (13,844) and 32,714 (14,512) ng · h/mL, respectively; Cmax, 5094 (2061) and 5064 (1864) ng/mL; Tmax, 2.92 (1.04) and 3.08 (1.01) hours.","Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24529292/),h,3.08,22441,DB00177,Valsartan
,20182825,area under curve,The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.,Preparation and bioavailability assessment of SMEDDS containing valsartan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20182825/),[h·ng] / [ml],607,23993,DB00177,Valsartan
,20182825,area under curve,The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.,Preparation and bioavailability assessment of SMEDDS containing valsartan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20182825/),h,1,23994,DB00177,Valsartan
,20182825,area under curve,The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.,Preparation and bioavailability assessment of SMEDDS containing valsartan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20182825/),h,445.36,23995,DB00177,Valsartan
,20182825,time,The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.,Preparation and bioavailability assessment of SMEDDS containing valsartan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20182825/),h,1,23996,DB00177,Valsartan
,20182825,time,The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.,Preparation and bioavailability assessment of SMEDDS containing valsartan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20182825/),h,1.36,23997,DB00177,Valsartan
,29212229,relative bioavailability,"In pharmacokinetic studies in rats, the relative bioavailability of the optimized granules was 107% and 222% of values obtained for SuSMEDDS and Diovan® powder, respectively.",Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212229/),%,107,27038,DB00177,Valsartan
,29212229,relative bioavailability,"In pharmacokinetic studies in rats, the relative bioavailability of the optimized granules was 107% and 222% of values obtained for SuSMEDDS and Diovan® powder, respectively.",Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29212229/),%,222,27039,DB00177,Valsartan
,26931777,terminal half-lives,"The mean terminal half-lives of sacubitril, LBQ657 and valsartan were ∼1.3, ∼12 and ∼21 h, respectively.","Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26931777/),h,∼1.3,34981,DB00177,Valsartan
,26931777,terminal half-lives,"The mean terminal half-lives of sacubitril, LBQ657 and valsartan were ∼1.3, ∼12 and ∼21 h, respectively.","Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26931777/),h,∼12,34982,DB00177,Valsartan
,26931777,terminal half-lives,"The mean terminal half-lives of sacubitril, LBQ657 and valsartan were ∼1.3, ∼12 and ∼21 h, respectively.","Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26931777/),h,∼21,34983,DB00177,Valsartan
,32023909,IC50,"In HEK293 cells overexpressing drug transporters, the protopanaxadiol (PPD)-type ginsenosides- Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2-inhibited human OATP1B1 and OATP1B3 transporters (IC50 values of 7.99-68.2 µM for OATP1B1; 1.36-30.8 µM for OATP1B3), suggesting the herb-drug interaction of PPD-type ginsenosides involving OATPs.",Herb-Drug Interaction of Red Ginseng Extract and Ginsenoside Rc with Valsartan in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32023909/),μM,7.99-68.2,39556,DB00177,Valsartan
,32023909,IC50,"In HEK293 cells overexpressing drug transporters, the protopanaxadiol (PPD)-type ginsenosides- Rb1, Rb2, Rc, Rd, Rg3, compound K, and Rh2-inhibited human OATP1B1 and OATP1B3 transporters (IC50 values of 7.99-68.2 µM for OATP1B1; 1.36-30.8 µM for OATP1B3), suggesting the herb-drug interaction of PPD-type ginsenosides involving OATPs.",Herb-Drug Interaction of Red Ginseng Extract and Ginsenoside Rc with Valsartan in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32023909/),μM,1.36-30.8,39557,DB00177,Valsartan
,19934029,peak plasma concentrations,"In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours).","Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934029/),h,1.6-4.9,43107,DB00177,Valsartan
,19934029,peak plasma concentrations,"In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours).","Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934029/),h,0.5-1.1,43108,DB00177,Valsartan
,19934029,peak plasma concentrations,"In healthy participants, a randomized, double-blind, placebo-controlled study (n = 80) of single-dose (200-1200 mg) and multiple-dose (50-900 mg once daily for 14 days) oral administration of LCZ696 showed that peak plasma concentrations were reached rapidly for valsartan (1.6-4.9 hours), AHU377 (0.5-1.1 hours), and its active moiety, LBQ657 (1.8-3.5 hours).","Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934029/),h,1.8-3.5,43109,DB00177,Valsartan
,26156887,relative bioavailability,In vivo pharmacokinetic studies showed 199 % relative bioavailability with significant improvement (p < 0.05) in area under the curve compared to valsartan pure drug.,Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26156887/),%,199,44245,DB00177,Valsartan
,22472448,V/V,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),,3.5,48975,DB00177,Valsartan
,22472448,flow rate,"VAL, AML and HCT were resolved using a Gemini C18 column and mobile phase gradient starting from 20 % acetonitrile and 80 % 10 mmol L(-1) ammonium formate (V/V, pH 3.5 ± 0.2, by formic acid) to 70 % acetonitrile and 30 % 10 mmol L(-1) ammonium formate, over 20 minutes, with a flow rate of 1 mL min(-1).","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),[ml] / [min],1,48976,DB00177,Valsartan
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,76.5,48977,DB00177,Valsartan
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,72.0,48978,DB00177,Valsartan
,22472448,extraction recoveries,"Mean extraction recoveries of three QCs for the triple drug combination were 76.5 (VAL), 72.0 (AML) and 73.0 (HCT) % for human plasma.","Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22472448/),%,73.0,48979,DB00177,Valsartan
,18787797,flow rate,"After a simple protein precipitation using methanol, the analytes were separated on a Phenomenex Luna C(18) column using 42% acetonitrile with 15 mM potassium dihydrogenphosphate in water (pH 2.0; adjusted with phosphoric acid) as the mobile phase at a flow rate of 1.2 mL/min.",Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18787797/),[ml] / [min],1.2,53096,DB00177,Valsartan
,25853070,flow rate,"Chromatographic separation of amlodipine and valsartan was achieved on the Luna C18 (2)100A (150 × 4.6 mm, 5 μm) column using acetonitrile: 5 mM ammonium formate solution (80:20, v/v) as the mobile phase at a flow rate of 0.8 mL/min in isocratic mode.",Development and Validation of a LC-MS/MS Method for the Simultaneous Estimation of Amlodipine and Valsartan in Human Plasma: Application to a Bioequivalence Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853070/),[ml] / [min],0.8,61019,DB00177,Valsartan
,19277959,total run time,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),min,2.8,63151,DB00177,Valsartan
,19277959,flow rate,"The total run time was 2.8 min and the elution of SA, AD, VS and IS occurred at 1.81, 1.12, 1.14 and 1.81 min, respectively; this was achieved with a mobile phase consisting of 0.02 M ammonium formate (pH 4.5):acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-Terra C18 column.","Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19277959/),[ml] / [min],0.50,63152,DB00177,Valsartan
>,29188769,analytical recovery,The analytical recovery (>95%) was consistently observed and satisfactory sample stability was also found at different environmental conditions.,Chromatographic method development and validation for the determination of valsartan in biological fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188769/),%,95,66531,DB00177,Valsartan
,24974472,F(o-t),The F(o-t) and F(0-infinity) were (139.4 +/- 65.2)% and (137.5 +/- 61.2)% for valsartan of test preparations.,[Troubleshooting of bioinequivalence of compound valsartan tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974472/),%,139.4,72238,DB00177,Valsartan
,24974472,F(0-infinity),The F(o-t) and F(0-infinity) were (139.4 +/- 65.2)% and (137.5 +/- 61.2)% for valsartan of test preparations.,[Troubleshooting of bioinequivalence of compound valsartan tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974472/),%,137.5,72239,DB00177,Valsartan
,26006182,elimination half-life,Amlodipine elimination half-life during the first MARS™ session was calculated at 7.6 h.,Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006182/),h,7.6,84289,DB00177,Valsartan
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,1·91,94193,DB00177,Valsartan
,27321165,IC50,"Although no significant inhibition by LBQ657 (an active metabolite of sacubitril) and valsartan was observed, sacubitril inhibited OATP1B1 and OATP1B3 in vitro, with IC50 of 1·91 and 3·81 μm, respectively.",In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321165/),μm,3·81,94194,DB00177,Valsartan
,18258501,flow rate,"Ecabet and the I.S. valsartan were separated on a Venusil MP C18 analytical column using methanol-10mM ammonium acetate (75:25, v/v, pH 3.0) as mobile phase at a flow rate of 1.0 mL/min.",Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18258501/),[ml] / [min],1.0,108225,DB00177,Valsartan
,26961969,PDI,"The mean particle size and PDI of the optimized nanocrystal batch V4 was reported as 211 nm and 0.117, respectively.",Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961969/),,0.117,112580,DB00177,Valsartan
,26961969,lag times,Coated formulation CV4F showed two spikes in release profile after successive lag times of 235 and 390 min.,Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961969/),min,235,112581,DB00177,Valsartan
,26961969,lag times,Coated formulation CV4F showed two spikes in release profile after successive lag times of 235 and 390 min.,Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961969/),min,390,112582,DB00177,Valsartan
,26961969,bioavailability,The pharmacokinetic study revealed that the bioavailability of optimized formulation (72.90%) was significantly higher than the commercial Diovan tablet (30.18%).,Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961969/),%,72.90,112583,DB00177,Valsartan
,26961969,bioavailability,The pharmacokinetic study revealed that the bioavailability of optimized formulation (72.90%) was significantly higher than the commercial Diovan tablet (30.18%).,Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961969/),%,30.18,112584,DB00177,Valsartan
,26961539,time to reach maximum plasma concentration (T max),"Following oral administration, LCZ696 delivered systemic exposure to sacubitril, LBQ657 and valsartan with a median time to reach maximum plasma concentration (T max) ranging from 0.50 to 1.25, 2.00 to 3.00 and 1.50 to 2.50 h, respectively, over the investigated dose range.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,0.50 to 1.25,116481,DB00177,Valsartan
,26961539,time to reach maximum plasma concentration (T max),"Following oral administration, LCZ696 delivered systemic exposure to sacubitril, LBQ657 and valsartan with a median time to reach maximum plasma concentration (T max) ranging from 0.50 to 1.25, 2.00 to 3.00 and 1.50 to 2.50 h, respectively, over the investigated dose range.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,2.00 to 3.00,116482,DB00177,Valsartan
,26961539,time to reach maximum plasma concentration (T max),"Following oral administration, LCZ696 delivered systemic exposure to sacubitril, LBQ657 and valsartan with a median time to reach maximum plasma concentration (T max) ranging from 0.50 to 1.25, 2.00 to 3.00 and 1.50 to 2.50 h, respectively, over the investigated dose range.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,1.50 to 2.50,116483,DB00177,Valsartan
,26961539,terminal elimination half-life (T 1/2),"The mean terminal elimination half-life (T 1/2) ranged from 0.89 to 1.35, 8.57 to 9.24 and 5.33 to 7.91 h for sacubitril, LBQ657 and valsartan, respectively.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,0.89 to 1.35,116484,DB00177,Valsartan
,26961539,terminal elimination half-life (T 1/2),"The mean terminal elimination half-life (T 1/2) ranged from 0.89 to 1.35, 8.57 to 9.24 and 5.33 to 7.91 h for sacubitril, LBQ657 and valsartan, respectively.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,8.57 to 9.24,116485,DB00177,Valsartan
,26961539,terminal elimination half-life (T 1/2),"The mean terminal elimination half-life (T 1/2) ranged from 0.89 to 1.35, 8.57 to 9.24 and 5.33 to 7.91 h for sacubitril, LBQ657 and valsartan, respectively.","Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26961539/),h,5.33 to 7.91,116486,DB00177,Valsartan
,17146658,ED50,"The ED50 for angiotensin II in the subjects with 1166A/C [95% confidence interval (CI): 4.30 approximately 14.02 ng/kg/min] was significantly lower than in those with 1166A/A (95% CI: 14.23 approximately 28.77 ng/kg/min), while the E(max) for angiotensin II and EC50 for valsartan was similar in both genotype groups.",Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17146658/),[ng] / [kg·min],4.30 approximately 14.02,126188,DB00177,Valsartan
,17146658,ED50,"The ED50 for angiotensin II in the subjects with 1166A/C [95% confidence interval (CI): 4.30 approximately 14.02 ng/kg/min] was significantly lower than in those with 1166A/A (95% CI: 14.23 approximately 28.77 ng/kg/min), while the E(max) for angiotensin II and EC50 for valsartan was similar in both genotype groups.",Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17146658/),[ng] / [kg·min],14.23 approximately 28.77,126189,DB00177,Valsartan
,19179299,Body weight-normalized apparent oral clearance,Body weight-normalized apparent oral clearance ranges from 0.061 to 0.089 L/h/kg.,Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179299/),[l] / [h·kg],0.061 to 0.089,126540,DB00177,Valsartan
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00177,Valsartan
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00177,Valsartan
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00177,Valsartan
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00177,Valsartan
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00177,Valsartan
,26381913,relative bioavailability,"Following single oral administration of proliposomes and SNEDDS, a relative bioavailability of 202.36 and 196.87%, respectively, was achieved compared to pure valsartan suspension.",Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26381913/),%,202.36,134641,DB00177,Valsartan
,26381913,relative bioavailability,"Following single oral administration of proliposomes and SNEDDS, a relative bioavailability of 202.36 and 196.87%, respectively, was achieved compared to pure valsartan suspension.",Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26381913/),%,196.87,134642,DB00177,Valsartan
,9342579,Cmax,"Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8).","Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342579/),h,2,135291,DB00177,Valsartan
<,9342579,t1/2 lambda 1,"Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8).","Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342579/),h,1,135292,DB00177,Valsartan
,9342579,terminal,"Absorption and distribution of valsartan were rapid (Cmax, 2 h; t1/2 lambda 1 < 1 h), followed by a slower terminal elimination phase (t1/2 lambda 2, 6 h) on days 1 and 8, with little accumulation in plasma (increase of 20% on day 8).","Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342579/),h,6,135293,DB00177,Valsartan
,24937379,solubility,"The purpose of the present study was to formulate and evaluate nanosuspension of Valsartan (VAL), a poorly water soluble and low bioavailable drug (solubility of 0.18 mg mL(-1); 23% of oral bioavailability) with the aim of improving the aqueous solubility thus the bioavailability and consequently better anti-hypertensive activity.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),[mg] / [ml],0.18,140235,DB00177,Valsartan
,24937379,oral bioavailability,"The purpose of the present study was to formulate and evaluate nanosuspension of Valsartan (VAL), a poorly water soluble and low bioavailable drug (solubility of 0.18 mg mL(-1); 23% of oral bioavailability) with the aim of improving the aqueous solubility thus the bioavailability and consequently better anti-hypertensive activity.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),%,23,140236,DB00177,Valsartan
,24937379,Cmax,"The level of VAL in rat plasma treated with VAL-NS showed significant difference (p ≤ 0.005) in Cmax (1627.47 ± 112.05 ng mL(-1)), Tmax (2.00 h) and AUC0→24 (13279.2 ± 589.426 ng h mL(-1)) compared to VAL-Susp that was found to be 1384.73 ± 98.76 ng mL(-1), 3.00 h and 9416.24 ± 218.48 ng h mL(-1) respectively.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),[ng] / [ml],1627.47,140237,DB00177,Valsartan
,24937379,Tmax,"The level of VAL in rat plasma treated with VAL-NS showed significant difference (p ≤ 0.005) in Cmax (1627.47 ± 112.05 ng mL(-1)), Tmax (2.00 h) and AUC0→24 (13279.2 ± 589.426 ng h mL(-1)) compared to VAL-Susp that was found to be 1384.73 ± 98.76 ng mL(-1), 3.00 h and 9416.24 ± 218.48 ng h mL(-1) respectively.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),h,2.00,140238,DB00177,Valsartan
,24937379,AUC0→24,"The level of VAL in rat plasma treated with VAL-NS showed significant difference (p ≤ 0.005) in Cmax (1627.47 ± 112.05 ng mL(-1)), Tmax (2.00 h) and AUC0→24 (13279.2 ± 589.426 ng h mL(-1)) compared to VAL-Susp that was found to be 1384.73 ± 98.76 ng mL(-1), 3.00 h and 9416.24 ± 218.48 ng h mL(-1) respectively.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),[h·ng] / [ml],13279.2,140239,DB00177,Valsartan
,24937379,AUC0→24,"The level of VAL in rat plasma treated with VAL-NS showed significant difference (p ≤ 0.005) in Cmax (1627.47 ± 112.05 ng mL(-1)), Tmax (2.00 h) and AUC0→24 (13279.2 ± 589.426 ng h mL(-1)) compared to VAL-Susp that was found to be 1384.73 ± 98.76 ng mL(-1), 3.00 h and 9416.24 ± 218.48 ng h mL(-1) respectively.",Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937379/),[h·ng] / [ml],9416.24,140240,DB00177,Valsartan
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.22-0.34,141590,DB00177,Valsartan
,29604332,time to reach peak (Tmax),"In addition, there was an increasing trend in time to reach peak (Tmax) of VAL in FDCs, where it was increased by 0.22-0.34 h in mean and 0.40-0.44 h in median, except the combination of VAL/HCT at 160/12.5 mg.",Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604332/),h,0.40-0.44,141591,DB00177,Valsartan
,26663350,IC50 values,"Gemfibrozil and gemfibrozil 1-O-β glucuronide inhibited the cellular uptake of valsartan with IC50 values (µm) of 39.3 and 20.4, respectively, in MDCK/OATP1B1, while they were less interactive with OATP1B3.",Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663350/),µ,39.3,145477,DB00177,Valsartan
,26663350,IC50 values,"Gemfibrozil and gemfibrozil 1-O-β glucuronide inhibited the cellular uptake of valsartan with IC50 values (µm) of 39.3 and 20.4, respectively, in MDCK/OATP1B1, while they were less interactive with OATP1B3.",Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663350/),µ,20.4,145478,DB00177,Valsartan
,20367177,solubility,"Among the formulations tested, the valsartan-loaded gelatin microcapsule at the weight ratio of valsartan/gelatin/HPMC of 1/2/1 gave excellent drug solubility of approximately 2 microg/ml and dissolution of 70% at 1 h.",Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20367177/),[μg] / [ml],2,152020,DB00177,Valsartan
,19936896,"K (m,u)","The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),muM,28.4,153603,DB00177,Valsartan
,19936896,V (max),"The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),[pM] / [mg·min],1318,153604,DB00177,Valsartan
,19936896,P (dif),"The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),[μl] / [mg·min],1.21,153605,DB00177,Valsartan
,19936896,"K (m,u)","The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),μM,44.4,153606,DB00177,Valsartan
,19936896,V (max),"The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),[pM] / [mg·min],304,153607,DB00177,Valsartan
,19936896,P (dif),"The uptake rate of valsartan was higher for rat hepatocytes (K (m,u) = 28.4 +/- 3.7 muM, V (max) = 1318 +/- 176 pmol/mg/min and P (dif) = 1.21 +/- 0.42 microl/mg/min) compared to human hepatocytes (K (m,u) = 44.4 +/- 14.6 microM, V (max) = 304 +/- 85 pmol/mg/min and P (dif) = 0.724 +/- 0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19936896/),[μl] / [mg·min],0.724,153608,DB00177,Valsartan
,27405507,m/,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,612.1,158133,DB00177,Valsartan
,27405507,m/,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,280.2,158134,DB00177,Valsartan
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,436.0,158135,DB00177,Valsartan
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,235.1,158136,DB00177,Valsartan
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,285.1,158137,DB00177,Valsartan
,27405507,m/z,"The analytes were ionized by positive electrospray ion and detected in the multi-reaction monitoring mode with m/z 612.1 → 280.2 for lercanidipine, m/z 436.0 → 235.1 for valsartan and m/z 285.1 → 193.1 for diazepam, the internal standard.",Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),,193.1,158138,DB00177,Valsartan
,27405507,recoveries,The recoveries of the analytes were in the range of 98-103%.,Simultaneous Determination of a Fixed-Dose Combination of Lercanidipine and Valsartan in Human Plasma by LC-MS-MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27405507/),%,98-103,158139,DB00177,Valsartan
,32485217,critical micelle concentration,"With approximately 75% weight of S-SuSMEDDS, no distinct crystallinity of VST was observed in S-SDM, resulting in critical micelle concentration value of 32 μg/mL.",Optimization of solid self-dispersing micelle for enhancing dissolution and oral bioavailability of valsartan using Box-Behnken design. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32485217/),[μg] / [ml],32,161162,DB00177,Valsartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,60,165770,DB00177,Valsartan
,9438775,oral bioavailability,"Irbesartan has the highest oral bioavailability in its class (60% to 80%) and, unlike valsartan, its absorption is not affected by food.","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),%,80,165771,DB00177,Valsartan
,9438775,elimination half-life,"Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h).","The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9438775/),h,11 to 15,165772,DB00177,Valsartan
,22192643,tmax,"Following the single-dose oral administration of valsartan/amlodipine 80/5 mg, valsartan and amlodipine plasma concentrations reached peak levels at median tmax of 3 and 6 h, respectively.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,3,171076,DB00177,Valsartan
,22192643,tmax,"Following the single-dose oral administration of valsartan/amlodipine 80/5 mg, valsartan and amlodipine plasma concentrations reached peak levels at median tmax of 3 and 6 h, respectively.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,6,171077,DB00177,Valsartan
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,7.7,171078,DB00177,Valsartan
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,8.6,171079,DB00177,Valsartan
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,47,171080,DB00177,Valsartan
,22192643,elimination half-lives,"These concentrations declined thereafter, with mean elimination half-lives of 7.7 h (single dose) and 8.6 h (multiple dose) for valsartan, and 47 h (single dose) and 45 h (multiple dose) for amlodipine.",Pharmacokinetics of single and multiple oral doses of valsartan/amlodipine (80/5 mg) in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22192643/),h,45,171081,DB00177,Valsartan
,31631736,relative bioavailabilities,"The relative bioavailabilities of Su-SMEDDS-T20, Su-SMEDDS-T80, and Su-SMEDDS-CR were 262%, 470%, and 458%, respectively, compared with the VST suspension.",Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31631736/),%,262,173827,DB00177,Valsartan
,31631736,relative bioavailabilities,"The relative bioavailabilities of Su-SMEDDS-T20, Su-SMEDDS-T80, and Su-SMEDDS-CR were 262%, 470%, and 458%, respectively, compared with the VST suspension.",Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31631736/),%,470,173828,DB00177,Valsartan
,31631736,relative bioavailabilities,"The relative bioavailabilities of Su-SMEDDS-T20, Su-SMEDDS-T80, and Su-SMEDDS-CR were 262%, 470%, and 458%, respectively, compared with the VST suspension.",Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31631736/),%,458,173829,DB00177,Valsartan
,25953248,flux,"The in vitro skin permeation study showed that the gel formulation of ultradeformable vesicles presented a flux value of 368.74 μg/cm(2)/h, in comparison to that of the traditional liposomal gel formulation, with an enhancement ratio of 26.91, through rat skin.",The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953248/),[μg] / [cm(2)·h],368.74,175242,DB00177,Valsartan
,25953248,enhancement ratio,"The in vitro skin permeation study showed that the gel formulation of ultradeformable vesicles presented a flux value of 368.74 μg/cm(2)/h, in comparison to that of the traditional liposomal gel formulation, with an enhancement ratio of 26.91, through rat skin.",The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25953248/),,26.91,175243,DB00177,Valsartan
,33355495,AUC(0- t ),"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μg] / [h·l],385.37,176093,DB00177,Valsartan
,33355495,AUC(0- t ),"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μg] / [h·l],851.64,176094,DB00177,Valsartan
,33355495,t1/2,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),h,5.46,176095,DB00177,Valsartan
,33355495,t1/2,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),h,6.34,176096,DB00177,Valsartan
,33355495,C max,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μg] / [l],62.64,176097,DB00177,Valsartan
,33355495,C max,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μg] / [l],83.87,176098,DB00177,Valsartan
,33355495,clearance rate,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[l] / [h·kg],10.92,176099,DB00177,Valsartan
,33355495,clearance rate,"In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05).",Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[l] / [h·kg],25.76,176100,DB00177,Valsartan
,33355495,half-life,The metabolic stability of valsartan was also decreased by ligustrazine as the half-life of valsartan in rat liver microsomes decreased from 37.12 ± 4.06 to 33.48 ± 3.56 min and the intrinsic clearance rate increased from 37.34 ± 3.84 to 41.40 ± 4.32 μL/min/mg protein (p < 0.05).,Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),min,37.12,176101,DB00177,Valsartan
,33355495,half-life,The metabolic stability of valsartan was also decreased by ligustrazine as the half-life of valsartan in rat liver microsomes decreased from 37.12 ± 4.06 to 33.48 ± 3.56 min and the intrinsic clearance rate increased from 37.34 ± 3.84 to 41.40 ± 4.32 μL/min/mg protein (p < 0.05).,Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),min,33.48,176102,DB00177,Valsartan
,33355495,intrinsic clearance rate,The metabolic stability of valsartan was also decreased by ligustrazine as the half-life of valsartan in rat liver microsomes decreased from 37.12 ± 4.06 to 33.48 ± 3.56 min and the intrinsic clearance rate increased from 37.34 ± 3.84 to 41.40 ± 4.32 μL/min/mg protein (p < 0.05).,Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μl] / [mg·min],37.34,176103,DB00177,Valsartan
,33355495,intrinsic clearance rate,The metabolic stability of valsartan was also decreased by ligustrazine as the half-life of valsartan in rat liver microsomes decreased from 37.12 ± 4.06 to 33.48 ± 3.56 min and the intrinsic clearance rate increased from 37.34 ± 3.84 to 41.40 ± 4.32 μL/min/mg protein (p < 0.05).,Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355495/),[μl] / [mg·min],41.40,176104,DB00177,Valsartan
,26773890,flow rate,"The chromatographic separation was obtained with reverse phase C18 column and the mobile phase composed of potassium phosphate buffer containing 0.025% trifluoroacetic acid (pH 2.5; 5mM) and acetonitrile including 0.025% trifluoroacetic acid (20:80, v/v) at 1.0mL/min flow rate.",Determination of manassantin B in rat plasma using a high performance liquid chromatography with fluorescence detection and its quantitative application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26773890/),[ml] / [min],1.0,179639,DB00177,Valsartan
,17331816,flow rate,"After a simple protein precipitation using acetonitrile, the analytes were separated on a Zorbax SB-Aq C18 column using acetonitrile-10mM ammonium acetate (60:40, v/v, pH 4.5) as mobile phase at a flow rate of 1.2 mL/min.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17331816/),[ml] / [min],1.2,182489,DB00177,Valsartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,35,184743,DB00177,Valsartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,23,184744,DB00177,Valsartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,31,184745,DB00177,Valsartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184746,DB00177,Valsartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],0.943,184747,DB00177,Valsartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184748,DB00177,Valsartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,16,184749,DB00177,Valsartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],3.39,184750,DB00177,Valsartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],5.48,184751,DB00177,Valsartan
,18307734,bioavailability,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),%,2.6 and 5.0,185713,DB00177,Valsartan
,18307734,IC50,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),[nM] / [l],0.6,185714,DB00177,Valsartan
,18307734,plasma half-life,"2. Aliskiren has a low bioavailability (between 2.6 and 5.0%) compensated by its high potency to inhibit renin (IC50: 0.6 nmol/L) and a long plasma half-life (23-36 h), which makes it suitable for once-daily dosing.",Renin inhibition with aliskiren. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307734/),h,23-36,185715,DB00177,Valsartan
,28444983,bioavailability,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),%,60,188020,DB00177,Valsartan
,28444983,tmax,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),h,1.5-3,188021,DB00177,Valsartan
,28444983,half-life,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),h,11,188022,DB00177,Valsartan
,28444983,IC50,"With its IC50 of 7.4 nM after 5 hr of drug washout in radioligand assays, AZL has a tighter and longer-lasting binding to the AT1 receptor by several orders of magnitude than other ARBs, which might lead to a more effective reduction in BP.","Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),nM,7.4,188023,DB00177,Valsartan
,11249553,elimination half-life,"The elimination half-life comes to about 7-8 h, valsartan is metabolised to a negligible extent and most of the drug is excreted via the faeces.",Valsartan: a novel angiotensin type 1 receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249553/),h,7-8,190430,DB00177,Valsartan
,28025969,extraction recovery,"The extraction recovery for valsartan varied between 89.3 and 97.8%, and the stability in all conditions was excellent.",Quantitative analysis of valsartan by two-dimensional liquid chromatography (2D-HPLC) and its application in a bioequivalence study in Chinese volunteers . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025969/),%,89.3 and 97.8,196139,DB00177,Valsartan
,28025969,relative bioavailability,The relative bioavailability was 103.9 ± 15.7%.,Quantitative analysis of valsartan by two-dimensional liquid chromatography (2D-HPLC) and its application in a bioequivalence study in Chinese volunteers . ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025969/),%,103.9,196140,DB00177,Valsartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],590.5,198029,DB00177,Valsartan
,23118328,C(max),"Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[ng] / [ml],282.1,198030,DB00177,Valsartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,3.1,198031,DB00177,Valsartan
,23118328,half-life,CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05).,"Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),h,2.3,198032,DB00177,Valsartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],1.07,198033,DB00177,Valsartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.48,198034,DB00177,Valsartan
,23118328,clearance,"CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001).","Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23118328/),[l] / [h·kg],0.35,198035,DB00177,Valsartan
,9174680,half-life,"The disposition of valsartan after an i.v. dose was characterized by biphasic decay kinetics, with a distribution phase (half-life 1.0 h), followed by a longer elimination phase (half-life 9.5 h).","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,1.0,202764,DB00177,Valsartan
,9174680,half-life,"The disposition of valsartan after an i.v. dose was characterized by biphasic decay kinetics, with a distribution phase (half-life 1.0 h), followed by a longer elimination phase (half-life 9.5 h).","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,9.5,202765,DB00177,Valsartan
,9174680,volume of distribution at steady state,"The volume of distribution at steady state was 16.9 l, and the total body clearance 2.2 l.h-1. 29% of the i.v. dose was recovered unchanged in the urine.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),l,16.9,202766,DB00177,Valsartan
,9174680,total body clearance,"The volume of distribution at steady state was 16.9 l, and the total body clearance 2.2 l.h-1. 29% of the i.v. dose was recovered unchanged in the urine.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h-·l,2.2,202767,DB00177,Valsartan
,9174680,terminal t1/2,"Thereafter, plasma levels declined biexponentially with a terminal t1/2 of 7.0 h.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,7.0,202768,DB00177,Valsartan
,9174680,t1/2,"Cmax was reached 1 h after administration of the solution, and t1/2 was 7.5 h.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,7.5,202769,DB00177,Valsartan
,9174680,fraction of dose absorbed,"The fraction of dose absorbed and systemically available after oral administration was 0.23 for the capsule and 0.39 for the solution, based on AUC.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),,0.23,202770,DB00177,Valsartan
,9174680,fraction of dose absorbed,"The fraction of dose absorbed and systemically available after oral administration was 0.23 for the capsule and 0.39 for the solution, based on AUC.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),,0.39,202771,DB00177,Valsartan
,9174680,systemically available,"The fraction of dose absorbed and systemically available after oral administration was 0.23 for the capsule and 0.39 for the solution, based on AUC.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),,0.23,202772,DB00177,Valsartan
,9174680,systemically available,"The fraction of dose absorbed and systemically available after oral administration was 0.23 for the capsule and 0.39 for the solution, based on AUC.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),,0.39,202773,DB00177,Valsartan
,9174680,half-life,"The first phase was rapid, with a half-life of 0.5 h and 0.9 h for solution and capsule, respectively.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,0.5,202774,DB00177,Valsartan
,9174680,half-life,"The first phase was rapid, with a half-life of 0.5 h and 0.9 h for solution and capsule, respectively.","Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,0.9,202775,DB00177,Valsartan
,9174680,half-life,The slower absorption phase was characterized by a half-life of 6.5 h for the solution and 3.5 h for the capsule.,"Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,6.5,202776,DB00177,Valsartan
,9174680,half-life,The slower absorption phase was characterized by a half-life of 6.5 h for the solution and 3.5 h for the capsule.,"Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174680/),h,3.5,202777,DB00177,Valsartan
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],98,205062,DB00177,Valsartan
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],138,205063,DB00177,Valsartan
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],63,205064,DB00177,Valsartan
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],96,205065,DB00177,Valsartan
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,14.2,205066,DB00177,Valsartan
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,9.1,205067,DB00177,Valsartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],84,205068,DB00177,Valsartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205069,DB00177,Valsartan
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205070,DB00177,Valsartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205071,DB00177,Valsartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205072,DB00177,Valsartan
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],441,205073,DB00177,Valsartan
,22670860,peak concentration,Quercetin significantly increases the plasma concentration of valsartan and peak concentration (70.45 µg/mL) was achieved at 3.5 h.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],70.45,205371,DB00177,Valsartan
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],53.12,205372,DB00177,Valsartan
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],40.15,205373,DB00177,Valsartan
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],28.68,205374,DB00177,Valsartan
,26289004,encapsulation efficiency,"Among the proliposomal formulations, F-V was found to have the highest encapsulation efficiency of 95.6 ± 2.9% with a vesicle size of 364.1 ± 14.9 nm.","Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26289004/),%,95.6,211657,DB00177,Valsartan
,26289004,relative bioavailability,"Following single oral administration of F-V formulation, a relative bioavailability of 202.36% was achieved as compared to pure valsartan.","Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26289004/),%,202.36,211658,DB00177,Valsartan
,19937834,"K(m,u)","The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),μM,28.4,212663,DB00177,Valsartan
,19937834,V(max),"The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),[pM] / [mg·min],1320,212664,DB00177,Valsartan
,19937834,P(dif),"The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),[μl] / [mg·min],1.21,212665,DB00177,Valsartan
,19937834,"K(m,u)","The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),μM,44.4,212666,DB00177,Valsartan
,19937834,V(max),"The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),[pM] / [mg·min],304,212667,DB00177,Valsartan
,19937834,P(dif),"The uptake rate of valsartan was higher for rat hepatocytes (K(m,u)=28.4+/-3.7 microM, V(max)=1320+/-180 pmol/mg/min, and P(dif) =1.21+/-0.42 microl/mg/min) compared to human hepatocytes (K(m,u)=44.4+/-14.6 microM, V(max)=304+/-85 pmol/mg/min, and P(dif)=0.724+/-0.271 microl/mg/min).",Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19937834/),[μl] / [mg·min],0.724,212668,DB00177,Valsartan
,24830648,flux,"The optimized valsartan gel formulation (VGF-OPT) yielded flux of 143.27 ± 7.11 µg/cm(2)/h and 27.55 ± 2.51 µg/cm(2)/h across rat and human cadaver skin, respectively.","Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24830648/),[μg] / [cm(2)·h],143.27,213473,DB00177,Valsartan
,24830648,flux,"The optimized valsartan gel formulation (VGF-OPT) yielded flux of 143.27 ± 7.11 µg/cm(2)/h and 27.55 ± 2.51 µg/cm(2)/h across rat and human cadaver skin, respectively.","Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24830648/),[μg] / [cm(2)·h],27.55,213474,DB00177,Valsartan
,27812915,drug loading efficiency,And the drug loading efficiency is approximately 14 wt%.,Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27812915/),wt%,14,215772,DB00177,Valsartan
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00177,Valsartan
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00177,Valsartan
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00177,Valsartan
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00177,Valsartan
,31467909,flow rate,The flow rate was 0.3 mL/min.,A High Throughput HPLC-MS/MS Method for Antihypertensive Drugs Determination in Plasma and Its Application on Pharmacokinetic Interaction Study with Shuxuetong Injection in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31467909/),[ml] / [min],0.3,224280,DB00177,Valsartan
,30144529,oral bioavailability,Valsartan was selected as a model drug due to its low oral bioavailability (~23%) caused by poor solubility of this drug in the low pH region of gastrointestinal tract (GIT) and presence of absorption window in the upper part of GIT.,Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30144529/),%,23,228795,DB00177,Valsartan
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB00177,Valsartan
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB00177,Valsartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB00177,Valsartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB00177,Valsartan
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB00177,Valsartan
,23313344,transdermal flux,Optimized nanoethosomal formulation with mean particle size is 103 ± 5.0 nm showed 89.34 ± 2.54% entrapment efficiency and achieved mean transdermal flux 801.36 ± 21.45 μg/cm(2)/h.,"Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313344/),[μg] / [cm(2)·h],801.36,241726,DB00177,Valsartan
,23313344,enhancement ratio,"Nanoethosomes proved significantly superior in terms of, amount of drug permeated in the skin, with an enhancement ratio of 43.38 ± 1.37 when compared to rigid liposomes.","Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313344/),,43.38,241727,DB00177,Valsartan
,33418444,flow rate,The mobile phase was acetonitrile and 0.1 % formic acid-water with gradient elution at a flow rate of 0.4 mL/min.,"Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),[ml] / [min],0.4,243622,DB00177,Valsartan
,33418444,Cmax,"The results indicated that low, medium and high doses of CDDP significantly increased the Cmax (6.47 ± 2.28, 6.51 ± 1.99, 7.04 ± 1.31 vs. 3.30 ± 1.87) of AZ, compared with that in the AZ single-drug group (p<0.05).","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,6.47,243623,DB00177,Valsartan
,33418444,Cmax,"The results indicated that low, medium and high doses of CDDP significantly increased the Cmax (6.47 ± 2.28, 6.51 ± 1.99, 7.04 ± 1.31 vs. 3.30 ± 1.87) of AZ, compared with that in the AZ single-drug group (p<0.05).","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,6.51,243624,DB00177,Valsartan
,33418444,Cmax,"The results indicated that low, medium and high doses of CDDP significantly increased the Cmax (6.47 ± 2.28, 6.51 ± 1.99, 7.04 ± 1.31 vs. 3.30 ± 1.87) of AZ, compared with that in the AZ single-drug group (p<0.05).","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,7.04,243625,DB00177,Valsartan
,33418444,Cmax,"The results indicated that low, medium and high doses of CDDP significantly increased the Cmax (6.47 ± 2.28, 6.51 ± 1.99, 7.04 ± 1.31 vs. 3.30 ± 1.87) of AZ, compared with that in the AZ single-drug group (p<0.05).","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,3.30,243626,DB00177,Valsartan
,33418444,AUC0-t,"The AUC0-t of AZ (47.77 ± 23.41, 50.69 ± 25.46, 54.50 ± 11.57 vs. 26.85 ± 16.79) tended to increase in combination with CDDP.","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,47.77,243627,DB00177,Valsartan
,33418444,AUC0-t,"The AUC0-t of AZ (47.77 ± 23.41, 50.69 ± 25.46, 54.50 ± 11.57 vs. 26.85 ± 16.79) tended to increase in combination with CDDP.","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,50.69,243628,DB00177,Valsartan
,33418444,AUC0-t,"The AUC0-t of AZ (47.77 ± 23.41, 50.69 ± 25.46, 54.50 ± 11.57 vs. 26.85 ± 16.79) tended to increase in combination with CDDP.","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,54.50,243629,DB00177,Valsartan
,33418444,AUC0-t,"The AUC0-t of AZ (47.77 ± 23.41, 50.69 ± 25.46, 54.50 ± 11.57 vs. 26.85 ± 16.79) tended to increase in combination with CDDP.","Compound danshen dripping pills affect the pharmacokinetics of azisartan by regulating the expression of cytochrome P450 2B1, 2C6, and 2C11 in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418444/),,26.85,243630,DB00177,Valsartan
,9041679,beta-Half-lives,beta-Half-lives of 6 +/- 1 h were observed.,"Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041679/),h,6,244411,DB00177,Valsartan
,9041679,half-life,"In a terminal elimination phase, low radioactivity levels decreased with a half-life of 81 +/- 33 h.","Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041679/),h,81,244412,DB00177,Valsartan
,9041679,total excretion,The total excretion within 7 days amounted to 99 +/- 1% of dose.,"Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041679/),%,99,244413,DB00177,Valsartan
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],168,247743,DB00177,Valsartan
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],121,247744,DB00177,Valsartan
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],418,247745,DB00177,Valsartan
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"1,160",247746,DB00177,Valsartan
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],955,247747,DB00177,Valsartan
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"2,801",247748,DB00177,Valsartan
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00177,Valsartan
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00177,Valsartan
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00177,Valsartan
,20112137,C (max),"The apparent rate of absorption of valsartan from the prepared tablets (C (max) = 2.879 microg/ml, t (max) = 1.08 h) was significantly higher than that of the conventional tablets (C (max) = 1.471 microg/ml, t (max) = 2.17 h), P < or = 0.05.","Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112137/),[μg] / [ml],2.879,251622,DB00177,Valsartan
,20112137,t (max),"The apparent rate of absorption of valsartan from the prepared tablets (C (max) = 2.879 microg/ml, t (max) = 1.08 h) was significantly higher than that of the conventional tablets (C (max) = 1.471 microg/ml, t (max) = 2.17 h), P < or = 0.05.","Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112137/),h,1.08,251623,DB00177,Valsartan
,20112137,C (max),"The apparent rate of absorption of valsartan from the prepared tablets (C (max) = 2.879 microg/ml, t (max) = 1.08 h) was significantly higher than that of the conventional tablets (C (max) = 1.471 microg/ml, t (max) = 2.17 h), P < or = 0.05.","Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112137/),[μg] / [ml],1.471,251624,DB00177,Valsartan
,20112137,t (max),"The apparent rate of absorption of valsartan from the prepared tablets (C (max) = 2.879 microg/ml, t (max) = 1.08 h) was significantly higher than that of the conventional tablets (C (max) = 1.471 microg/ml, t (max) = 2.17 h), P < or = 0.05.","Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112137/),h,2.17,251625,DB00177,Valsartan
,20112137,relative bioavailability,The relative bioavailability calculated as the ratio of mean total area under the plasma concentration-time curve for the orodispersible tablets relative to the conventional ones was 135%.,"Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20112137/),%,135,251626,DB00177,Valsartan
,18611061,absolute bioavailability,The absolute bioavailability of aliskiren is 2.6%.,Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),%,2.6,252071,DB00177,Valsartan
,18611061,accumulation factor,"Steady-state plasma concentrations of aliskiren are reached after 7-8 days of once-daily dosing, and the accumulation factor for aliskiren is approximately 2.",Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),,2,252072,DB00177,Valsartan
,18716369,vascular peroxynitrite,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254078,DB00177,Valsartan
,18716369,concentration,The vascular peroxynitrite concentration was 1.6 pmol/mg protein in the control group and significantly less than those in the P- and V-monotherapy-groups.,Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18716369/),[pM] / [mg],1.6,254079,DB00177,Valsartan
,16678545,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of pravastatin in *1b/*1b carriers (47.4 +/- 19.9 ng.h/mL) was 65% of that in *1a/*1a carriers (73.2 +/- 23.5 ng.h/mL) (P = .049).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],47.4,257500,DB00177,Valsartan
,16678545,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of pravastatin in *1b/*1b carriers (47.4 +/- 19.9 ng.h/mL) was 65% of that in *1a/*1a carriers (73.2 +/- 23.5 ng.h/mL) (P = .049).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],73.2,257501,DB00177,Valsartan
,16678545,AUC,Carriers of *1b/*15 (38.2 +/- 15.9 ng.h/mL) exhibited a 45% lower AUC than *1a/*15 carriers (69.2 +/- 23.4 ng.h/mL) (P = .024).,"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],69.2,257502,DB00177,Valsartan
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],12.4,257503,DB00177,Valsartan
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],18.5,257504,DB00177,Valsartan
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],16.4,257505,DB00177,Valsartan
,16678545,AUC,"The AUC of temocapril also showed a similar trend (12.4 +/- 4.1 ng.h/mL for *1b/*1b carriers versus 18.5 +/- 7.7 ng.h/mL for *1a/*1a carriers [P = .061] and 16.4 +/- 5.0 ng.h/mL for *1b/*15 carriers versus 19.0 +/- 4.1 ng.h/mL for *1a/*15 carriers [P = .425]), whereas that of temocaprilat (active form of temocapril) was not significantly affected by the haplotype of OATP1B1.","Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678545/),[h·ng] / [ml],19.0,257506,DB00177,Valsartan
,26857923,droplet sizes,"The average droplet sizes of the optimized blank and drug-loaded SMEDDS formulations were 26.20 ± 1.43 and 33.34 ± 2.15 nm, and the melting points of them were 35.6 and 36.8 °C, respectively.",Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire 44/14. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857923/),nm,26.20,270152,DB00177,Valsartan
,26857923,droplet sizes,"The average droplet sizes of the optimized blank and drug-loaded SMEDDS formulations were 26.20 ± 1.43 and 33.34 ± 2.15 nm, and the melting points of them were 35.6 and 36.8 °C, respectively.",Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire 44/14. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857923/),nm,33.34,270153,DB00177,Valsartan
,26857923,melting points,"The average droplet sizes of the optimized blank and drug-loaded SMEDDS formulations were 26.20 ± 1.43 and 33.34 ± 2.15 nm, and the melting points of them were 35.6 and 36.8 °C, respectively.",Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire 44/14. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857923/),°c,35.6,270154,DB00177,Valsartan
,26857923,melting points,"The average droplet sizes of the optimized blank and drug-loaded SMEDDS formulations were 26.20 ± 1.43 and 33.34 ± 2.15 nm, and the melting points of them were 35.6 and 36.8 °C, respectively.",Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire 44/14. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26857923/),°c,36.8,270155,DB00177,Valsartan
